title: Topical glucocorticoid or pimecrolimus treatment suppresses thymic stromal lymphopoietin-related allergic inflammatory mechanism in an oxazolone-induced atopic dermatitis murine model.
abstract: Congenitally or early impaired skin barrier as the first event starting the 'atopic march' in atopic dermatitis (AD) patients can increase allergen penetration that results in sensitization, even in the airways, followed by asthma and allergic rhinitis. Thymic stromal lymphopoietin (TSLP) is a cytokine existing in high levels in AD skin and is considered as a novel therapeutic target for atopic disease. We generated oxazolone (Ox)-induced AD-like (Ox-AD) hairless mice and divided them into four groups according to the therapeutic challenges: topical glucocorticoid, pimecrolimus, emollient, and control (acetone-only treated). We assessed the functional studies of skin barrier, epidermal expressions of differentiation markers, IL-1α, TNF-α, proteinase-activated receptor-2 (PAR-2), TSLP and antimicrobial peptides (AMP), and serum IgE in each group. Topical glucocorticoid or pimecrolimus treatment improved AD-like skin lesions and barrier functions, and restored the epidermal expression of differentiation markers, IL-1α, TNF-α, PAR-2, and TSLP, in Ox-AD mice. The improvement was relatively better with the glucocorticoid than pimecrolimus. Epidermal AMP expression was restored by topical glucocorticoid, but not pimecrolimus. Our result showed that topical glucocorticoid or pimecrolimus improved the AD-like skin lesions and barrier impairment by suppressing TSLP-related allergic inflammation.
authors: Department of Dermatology, Yonsei University Wonju College of Medicine, 20 Ilsan-ro, Wonju, Republic of Korea.
authors: Na Young
authors: NY
authors: Yoon
authors: Min young
authors: My
authors: Jung
authors: Dong Hye
authors: DH
authors: Kim
authors: Hae Jin
authors: HJ
authors: Lee
authors: Eung Ho
authors: EH
authors: Choi
mesh_terms: D000276:Adjuvants, Immunologic / Q000633:toxicity; D000287:Administration, Topical; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers; D016207:Cytokines / Q000235:genetics / Q000378:metabolism*; D003877:Dermatitis, Contact / Q000188:drug therapy*; D004817:Epidermis / Q000187:drug effects / Q000502:physiology; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects; D008775:Methylprednisolone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D051379:Mice; D008812:Mice, Hairless; D010081:Oxazolone / Q000633:toxicity*; D010539:Permeability; D011498:Protein Precursors / Q000235:genetics / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D016559:Tacrolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000094632:Thymic Stromal Lymphopoietin
chemical_list: D000276:Adjuvants, Immunologic; D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D016207:Cytokines; D011498:Protein Precursors; D012333:RNA, Messenger; D010081:Oxazolone; C117268:pimecrolimus; C078007:methylprednisolone aceponate; D016559:Tacrolimus; D008775:Methylprednisolone; D000094632:Thymic Stromal Lymphopoietin; C000721967:TSLP protein, mouse